Cyrus Mozayeni, Pheon Therapeutics CEO

ADC biotech Pheon rais­es $120M to test three as­sets in the clin­ic

In­vestors con­tin­ue to flock to­ward an­ti­body-drug con­ju­gates.

Pheon Ther­a­peu­tics is the lat­est to catch the tail­winds of the boom­ing seg­ment of on­col­o­gy R&D. The Lon­don …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.